RxDoctor Payments Data

Dan Dan, MD

Clinical Cardiac Electrophysiology · Ogden, UTNPI 1326043472

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $34,325 of the $40,091 with a category attached, or 85.6%. 12 manufacturers reported payments, led by Medtronic at 57.0% of the total. Reporting peaked in 2020 at $15,652 and has fallen 77.3% since, to $3,555 in 2025.

$40,091in general payments, 2019–2025

Across 241 payments — averaging $166.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$23K
  • Biosense Webster, Inc.$13K
  • Abbott$3K
  • Medical Device Business Services, Inc.$606
  • Boston Scientific$330
  • Biotronik Inc.$137
  • plus $210 from 6 others
$13,230in research payments, 2019–2025

Across 1 payment — averaging $13,230 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Microport CRM USA Inc$13K

What the payments were for

  • Consulting fees$34,32586%
  • Travel & lodging$6062%
  • Food & beverage$5,15913%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,091 in reported general payments places this provider in the 55th percentile of 29 clinical cardiac electrophysiology providers in Utah.

See all clinical cardiac electrophysiology providers in Utah

Medicare billing

Part B allowed, 2024
$116,942
Medicare patients
778
Services billed
1,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$54,632
XareltoRivaroxaban23$22,766
Flecainide Acetate37$983
Metoprolol Succinate78$924
Amiodarone Hcl35$361
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$54,63254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 29 clinical cardiac electrophysiology providers in Utah.

Other clinical cardiac electrophysiology in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →